Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 53.49B 7.88B 6.9B 6.36B 5.89B 11.17B 748B 11.38B 76.25B 29.65B 369B 29.59B 28.95B 1,278B P/E 2026 *
39.3x
P/E 2027 * 32.5x
Enterprise Value 48.41B 7.13B 6.24B 5.76B 5.33B 10.11B 677B 10.3B 69.01B 26.83B 334B 26.78B 26.2B 1,157B EV / Sales 2026 *
6.02x
EV / Sales 2027 * 5.22x
Free-Float
61.14%
Yield 2026 *
0.97%
Yield 2027 * 1.16%
Manager TitleAgeSince
Chief Executive Officer 70 07/10/1998
Chief Executive Officer 49 19/01/2022
President - -
Director TitleAgeSince
Director/Board Member 49 18/07/2011
Chairman 70 07/10/1998
Director/Board Member 65 18/07/2011
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 8.33B
+2.96%+3.01%+59.87%+173.31% 1,070B
+3.05%+5.23%+72.11%+67.81% 624B
-0.04%+1.20%+35.72%+87.93% 450B
-2.58%-2.07%+27.62%+22.57% 328B
+1.36%+0.17%+29.90%+49.33% 284B
+1.98%+4.08%-25.78%-39.02% 217B
+0.45%+1.65%+25.65%+68.35% 198B
+5.21%+7.93%+21.99%+83.23% 161B
+1.48%-0.04%-4.64%-32.25% 135B
Average +0.78%+2.20%+26.94%+53.47% 385.27B
Weighted average by Cap. +0.29%+2.51%+41.85%+87.34%

Financials

2026 *2027 *
Net sales 8.05B 1.19B 1.04B 957M 887M 1.68B 113B 1.71B 11.48B 4.46B 55.46B 4.45B 4.36B 192B 9.56B 1.41B 1.23B 1.14B 1.05B 2B 134B 2.03B 13.62B 5.3B 65.84B 5.29B 5.17B 228B
Net income 1.41B 207M 181M 167M 155M 294M 19.68B 299M 2B 779M 9.69B 778M 761M 33.61B 1.72B 253M 221M 204M 189M 358M 24B 365M 2.44B 951M 11.82B 949M 928M 40.98B
Net Debt -5.08B -748M -655M -604M -560M -1.06B -71.06B -1.08B -7.24B -2.82B -34.99B -2.81B -2.75B -121B -4.41B -649M -568M -524M -485M -920M -61.64B -938M -6.28B -2.44B -30.35B -2.44B -2.38B -105B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-